Cambridge, Mass. – September 12, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the biotech leader in rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP607 for the prevention of chronic lung disease in extremely premature infants. SHP607, currently in phase 2 clinical development, is a recombinant human version of the naturally occurring protein complex of insulin-like growth factor 1 (IGF-1) and its most abundant binding protein, IGF binding protein-3 (IGFBP-3). IGF-1 plays an important role in the development of the fetus in the uterus.
The SHP607 Fast Track designation is supported by preclinical data and Phase 1 and 2 studies. The FDA's Fast Track process is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. However, it does not guarantee that the FDA will ultimately approve SHP607 or the timing of any such approval.
“We are pleased to achieve this regulatory milestone as we progress this very important clinical development program,” says Howard Mayer, M.D., Shire’s Head of Research and Development, ad interim. “There are no approved treatment options for chronic lung disease for premature infants, and we are aiming to change that. We are continuing to advance the SHP607 clinical program, which is well aligned with Shire’s focus on bringing innovative therapies to patients with rare diseases worldwide.”
About the SHP607 Clinical Development Program
Prior to Shire adding SHP607 to its clinical development pipeline in 2013 when it acquired privately held Premacure AB, a Phase I clinical trial was conducted and its results showed that the levels of IGF-1 were increased to within physiological levels and that administration of the investigational protein to preterm infants. Shire took over Premacure’s Phase 2 clinical trial, reporting topline results in June 2016, which did not meet the study’s primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition. The study, however, demonstrated clinically relevant effects in secondary endpoints related to the development of severe bronchopulmonary dysplasia (BPD), a chronic lung disease, and severe intraventricular hemorrhage (IVH), a type of brain injury, both of which have lifelong negative implications for normal development. There were no serious adverse events related to the investigational medicinal product.
Following the phase 2 study results, Shire initiated discussions with regulatory authorities in the United States, Europe and Japan to discuss an appropriate regulatory review pathway for SHP607. As a result of those discussions, Shire is in the process of developing a phase 2b/3 clinical trial SHP607 targeting a primary endpoint focused on chronic lung disease in extremely premature infants. Key secondary endpoints being explored include BPD and IVH.
Shire is currently conducting a five-year observational long-term outcomes study of patients who had been enrolled in the phase 2 study.
About IGF-1 and Complications Related to Extremely Premature Infants
IGF-1 is supplied by the mother until about 30 weeks of gestation when the fetus begins producing the growth factor on its own. Levels of IGF-1 dramatically decrease in infants born extremely premature (before 28 weeks of gestation), thereby increasing the risk for complications related to the lungs, brain, eyes, and other organs.
Approximately 28,000 infants in the United States are born extremely premature - before 28 weeks of gestation. Research suggests that 60% of extremely premature infants experience one or more severe complications related to prematurity, which include: IVH; BPD; or ROP. Severe complications can have life-long implications for the developing infant.
|Ian Karpemail@example.com||+1 781 482 9018|
|Robert Coatesfirstname.lastname@example.org||+44 1256 894874|
|Lisa Adleremail@example.com||+1 617 588 8607|
|Gwen Fisherfirstname.lastname@example.org||+1 781 482 9649|
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
a further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM 1A: Risk Factors”, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.